Genfit - ADR

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné, and Bart Staels in September 1999 and is headquartered in Loos, France.

Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland ); September 2 6 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the publication of data demonstrating the effectiveness of its non-alcoholic steatohepatitis (NASH)1 diagnostic technology NIS4® by the FNIH's2 NIMBLE 3 project in the scientific journal, Nature Medicine 4 .

GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology

After losing some value lately, a hammer chart pattern has been formed for GENFIT S.A. Unsponsored ADR (GNFT), indicating that the stock has found support.

GENFIT S.A. Unsponsored ADR (GNFT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Lille (France ), Cambridge (Massachusetts, United States), Zurich (Switzerland) , September 05 , 202 3 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it will participate in the following upcoming investor conferences.

GENFIT to Participate in Upcoming Investor Conferences

Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland ); August 10 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the publication of new data on the clinical performance of NIS2+™ in older patients, for the detection of at-risk nonalcoholic steatohepatitis (NASH) in Hepatology Communications 1.

GENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+™ in Older Patients in Hepatology Communications

GENFIT (NASDAQ:GNFT) shares fell 5% after initially rising on positive results from its clinical trial with partner Ipsen for the investigational therapeutic elafibranor in patients with the rare cholestatic liver disease primary biliary cholangitis (PBC).   The two companies announced on Friday that the Phase 3 ELATIVE trial met its primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to the placebo.

Genfit shares fall despite positive trial results for rare cholestatic liver disease therapeutic

Apple

NIKE

Here comes the third quarter, next stop, the rest of the year. Judging by stock futures action, the first half could end on a positive note.

These strategists say investors need quality, so sell Tesla and AMD, and buy these stocks instead.

The U.S.-listed stock of Genfit S.A. GNFT, -5.48% GNFT, +22.56% soared 27% premarket Friday, after the French biotech and partner Ipsen IPSEY, +7.22% IPN, +0.27% announced positive results from a late-stage trial of a treatment for a rare liver disease.

U.S.-listed shares of Genfit soar 24% after positive results from late-stage trial of treatment for rare type of liver disease

Paris ( France ) ; Ju ne 30 , 202 3 - Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced positive topline data from the pivotal ELATIVE® Phase III trial. In the trial the efficacy and safety of elafibranor, an investigational dual α,δ PPAR agonist, is being assessed for the treatment of patients with the rare cholestatic liver disease, primary biliary cholangitis (PBC), who have an inadequate response or intolerance to the current standard of care therapy, ursodeoxycholic acid (UDCA).

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease

PARIS, FRANCE, 30 June   20 23 – Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced positive topline data from the pivotal ELATIVE Phase III trial. In the trial the efficacy and safety of elafibranor, an investigational dual α,δ PPAR agonist, is being assessed for the treatment of patients with the rare cholestatic liver disease, primary biliary cholangitis (PBC), who have an inadequate response or intolerance to the current standard of care therapy, ursodeoxycholic acid (UDCA).

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease

Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland ); June 7 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it will present new data at the EASL Congress which will take place on June 21-24, 2023 in Vienna, Austria.

GENFIT Announces New Data at the European Association for the Study of the Liver (EASL) Congress 2023

Seal Rock eligible to receive payments up to €100 million, including regulatory, clinical, and commercial milestone payments, plus tiered royalties SEATTLE , May 31, 2023 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, today announced it has entered into an out-licensing agreement with GENFIT (Nasdaq and Euronext: GNFT) for the development of an injectable formulation of SRT-015 for acute liver disease, including Acute-on-Chronic Liver Failure (ACLF). Under the agreement, Seal Rock Therapeutics is eligible for payments up to €100 million, including regulatory, clinical, and commercial milestone payments, plus tiered royalties.

Seal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT for Development of Injectable Formulation of SRT-015 for Acute-on-Chronic Liver Disease (ACLF)

Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); Ma y 3 1 , 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases characterized by high unmet medical needs, today announced it has licensed the exclusive worldwide rights of ASK1 Inhibitor SRT-015 (injectable formulation in acute liver disease2) from Seal Rock Therapeutics, a Seattle, Washington (USA) based clinical stage company developing first-in-class and best-in-class kinase inhibitors.

GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset

Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); May 24 , 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the results of the Combined Shareholders Meeting which took place on May 24, 2023. The quorum on first convening amounted to 29.54% and shareholders approved all of the resolutions, with the exception of resolution n°26 which was rejected in accordance with the recommendations of the Board of Directors.

GENFIT: May 24, 2023 Combined Shareholders Meeting results

Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland ); May 23 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the publication of the development and validation of NIS2+™ in the Journal of Hepatology .1

GENFIT Announces Publication of the Development and Validation of NIS2+™ in the Journal of Hepatology

Lille (France); Cambridge, ( Massachusetts, United States); Zurich (Switzerland); May 11, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced its cash position as of March 31, 2023 and revenues for the first three months of 20231.

GENFIT Reports First Quarter 2023 Financial Information

Results from the phase 3 ELATIVE study, using elafibranor to treat patients with primary biliary cholangitis, are expected to be released before end of Q2 of 2023. The primary biliary cholangitis market is expected to reach $1.7 billion by 2029.

Genfit: Major Data Release Before End Of Q2 Of 2023 Could Get Ball Rolling

Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland); May 9 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it is presenting Phase 1 clinical data evaluating NTZ as part of its Acute-on-Chronic Liver Failure (ACLF) Program at Digestive Disease Week®, taking place from May 6-9, 2023 in Chicago, Illinois (USA).

GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week® as part of its ACLF Program

GENFIT Announces Publication of Extra-Financial Performance Report 2022

Lille ( France ) ; Cambridge ( Massachusetts, United States ) ; Zurich (Switzerland) ; April 19 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced that it published in the April 19, 2023 French legal announcements bulletin n°47 (Bulletin des Annonces Légales Obligatoires) its convening notice that the Combined Shareholders Meeting will be held on May 24, 2023, at 10:00am (CET), at the Faculty of Pharmaceutical Sciences in Lille, located at Parc Eurasanté, 3 rue du Professeur Laguesse, 59000 Lille, France.

GENFIT Annual Combined General Meeting of May 24, 2023 — Availability of Preparatory Documents

Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland); April 18 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced the filing of its 2022 Universal Registration Document with the Autorité des marchés financiers (AMF) and its Annual Report on Form 20-F for the year ended December 31, 2022 with the U.S. Securities and Exchange Commission (SEC).

GENFIT Announces Publication of the 2022 Universal Registration Document and the 2022 Annual Report on Form 20-F

Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 13, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases characterized by high unmet medical needs, today announced annual financial results for the year ended December 31, 2022. A summary of the consolidated financial statements is included further below.

GENFIT Reports Full-Year 2022 Financial Results and Provides Corporate Update

Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); February 28, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced its cash position as of December 31, 2022 and revenues for 2022.

GENFIT Announces Revenues and Cash Position as of December 31, 2022

Genfit is a relatively low-beta play offering investors tactical upside with a potential re-rating to the upside. Investors have rewarded the company's pipeline assets to date, in addition to emerging data from its non-invasive technologies.

Genfit: Catching Strong Bid With Emerging Data (Technical Analysis)

Chimerix

Harmony Biosciences Holdings

iTeos Therapeutics, Inc.

Regeneron Pharmaceuticals

Selecta Biosciences

Vertex Pharmaceuticals

While unpredictable compared to other sectors due to the ebb and flow of clinical trials, the best biotech stocks to buy offer investors incredible upside opportunities. Better yet, the volatility largely centers on developments of the industry itself rather than the broader economy.

The 7 Best Biotech Stocks to Buy for February 2023

Lille (France ), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 24 , 202 3 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced its provisional financial calendar for 2023.

News for Genfit - ADR Stock (GNFT)